Methylmalonic Acidemia (MMA) Market Report 2025

The methylmalonic acidemia (MMA) market size has grown strongly in recent years. It will grow from $9.39 billion in 2024 to $9.97 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth observed in the historical period can be attributed to factors such as the rising incidence of metabolic disorders and vitamin deficiencies, increased healthcare spending, greater health consciousness, a higher prevalence of genetic disorders, and growing demand from various end-user industries.

The methylmalonic acidemia (MMA) market size is expected to see strong growth in the next few years. It will grow to $12.5 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth projected for the forecast period is driven by factors such as the expansion of newborn screening programs, increased awareness among healthcare professionals, advancements in gene therapy, growing investments in rare disease research, and improved availability of specialized treatments. Key trends expected during this period include advancements in gene editing technologies, enhanced diagnostic techniques for early detection, progress in enzyme replacement therapies, the adoption of precision medicine approaches, and the growing implementation of newborn genetic screening programs.

The rising prevalence of metabolic disorders and vitamin deficiencies is expected to drive the growth of the methylmalonic acidemia (MMA) market. Metabolic disorders are conditions where the body struggles to process certain nutrients, produce energy, or regulate chemical reactions within cells. Vitamin deficiencies occur when the body lacks enough specific vitamins to function properly. The increase in metabolic disorders and vitamin deficiencies is largely attributed to poor diets, sedentary lifestyles, and heightened stress levels. Modern diets, which are often rich in processed foods, sugars, and unhealthy fats while lacking essential nutrients, contribute to deficiencies in vitamins and minerals. These metabolic disorders and vitamin deficiencies, especially vitamin B12 deficiency, disrupt methylmalonyl-CoA metabolism, leading to the buildup of methylmalonic acid and worsening MMA. For example, in November 2024, the National Institutes of Health reported that the prevalence of vitamin B12 deficiency rose from 4.6% to 5.2%, adding 507 cases between the third and fourth quarters of 2023. As a result, the growing incidence of metabolic disorders and vitamin deficiencies is fueling the expansion of the MMA market.

Leading companies in the MMA market are focusing on developing innovative solutions, such as mRNA-based therapies, to improve treatment outcomes by targeting the genetic causes of MMA and enhancing enzyme function to reduce the accumulation of toxic metabolites in affected individuals. mRNA-based therapies use messenger RNA to instruct cells to produce specific proteins that help treat diseases, including genetic disorders. For example, in June 2024, Moderna, Inc., a US-based pharmaceutical and biotechnology company, received FDA approval to include mRNA-3705 in the START pilot program, a significant advancement for rare disease treatments. mRNA-3705 is an investigational therapy for MMA caused by MUT deficiency, designed to restore the missing enzyme using mRNA technology. The therapy uses Moderna's proprietary lipid nanoparticle (LNP) system, also employed in the mRNA-3927 program for propionic acidemia. The FDA has granted mRNA-3705 orphan drug, fast track, and rare pediatric disease designations, expediting its development and clinical progress.

In October 2022, Alexion Pharmaceuticals, a US-based biopharmaceutical company, acquired LogicBio Therapeutics for approximately $68.2 million. This acquisition aims to accelerate Alexion's growth in genomic medicines by utilizing unique technology, a talented rare disease research team, and expertise in preclinical development. LogicBio Therapeutics, Inc. is a US-based biotechnology company specializing in gene-editing and gene therapy solutions for rare genetic diseases, including MMA.

Major players in the methylmalonic acidemia (mma) market are Moderna Inc., Lonza Group Ltd., Alexion Pharmaceuticals Inc., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Wockhardt Limited, Spectrum Chemical Manufacturing Corp., Asklepios BioPharmaceutical Inc. (AskBio), Selecta Biosciences Inc., BTG International Inc., BridgeBio Pharma Inc., VectivBio Holding AG, Supriya Lifescience Ltd., Recordati Rare Diseases Inc., Agios Pharmaceuticals Inc., AdvaCare Pharma USA LLC, LogicBio Therapeutics Inc., HemoShear Therapeutics LLC, Manus Aktteva Biopharma LLP, Deccan Nutraceuticals Pvt. Ltd.

North America was the largest region in the methylmalonic acidemia (MMA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in methylmalonic acidemia (MMA) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the methylmalonic acidemia (MMA) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Methylmalonic acidemia (MMA) is a rare inherited metabolic disorder in which the body is unable to effectively break down certain proteins and fats due to a deficiency in the enzyme methylmalonyl-CoA mutase or a related coenzyme, vitamin B12. The severity of MMA symptoms can vary, but they often include vomiting, lethargy, poor feeding, developmental delay, seizures, and failure to thrive.

The primary indications for methylmalonic acidemia (MMA) include acidosis, ketosis, hyperammonemia, hypoglycemia, hyperglycemia, neutropenia, and other related conditions. Acidosis refers to an excess of acid in the blood, resulting in a lower-than-normal pH level. There are various types of disorders associated with MMA, such as homocystinuria, isolated methylmalonic acidurias, and combined methylmalonic aciduria. These treatments and interventions are available through different distribution channels, including hospitals, pharmacies, clinics, and other outlets.

The methylmalonic acidemia (MMA) market research report is one of a series of new reports that provides methylmalonic acidemia (MMA) market statistics, including the methylmalonic acidemia (MMA) industry global market size, regional shares, competitors with the methylmalonic acidemia (MMA) market share, detailed methylmalonic acidemia (MMA) market segments, market trends, and opportunities, and any further data you may need to thrive in the methylmalonic acidemia (MMA) industry. This methylmalonic acidemia (MMA) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The methylmalonic acidemia (MMA) market consists of revenues earned by entities by providing services such as medical management, dietary support, and vitamin and medication therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The methylmalonic acidemia market includes sales of hydroxocobalamin, vitamin B12 tablets, other pharmaceutical and therapeutic products, dietary products, and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.